April 25, 2017 07:33 AM EDT
R&D
Pharma

Blitzed by tri­al fail­ures, On­coMed ax­es half its staff and re­trench­es around PhI drugs

John Carroll

Editor & Founder

On­coMed $OMED is cap­ping a dis­as­trous month with a move to ax half its staff, leav­ing 64 work­ers be­hind to ex­e­cute on a new busi­ness …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times